論文

査読有り 国際誌
2018年8月28日

A novel, nontoxic iron chelator, super-polyphenol, effectively induces apoptosis in human cancer cell lines.

Oncotarget
  • Toshiaki Ohara
  • ,
  • Yasuko Tomono
  • ,
  • Xing Boyi
  • ,
  • Sun Yingfu
  • ,
  • Kazuhiro Omori
  • ,
  • Akihiro Matsukawa

9
67
開始ページ
32751
終了ページ
32760
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.18632/oncotarget.25973

Iron chelation therapy is the main treatment for iron overload disease. Iron chelators were recently reported to be useful for cancer therapy; however, they cause side effects that make them difficult to use in some cancer patients. Thus, a novel oral iron chelator, super-polyphenol (SP), was developed for cancer therapy to decrease the side effects. SP is either water soluble or insoluble, and has different isoforms according to the number of side chains. Of these isoforms, water-soluble SP6 and SP10 appear to be the best candidates, as they have the strongest chelating abilities. In this study, we focused on the usefulness and safety of SP6 and SP10 as anti-cancer drugs, and examined their anti-cancer effects and toxicity. The results showed that SP6 and SP10 inhibited cancer cell proliferation by inducing apoptosis in HCT116, HSC-2, A549, and MCF-7 cancer cells. SP10 also inhibited tumor growth in an HCT116 xenograft model. SP6 and SP10 had no acute toxicities. An intravenous injection test revealed that SP6 and SP10 had better safety profiles than the iron chelator deferoxamine. In conclusion, SP is a novel oral iron chelator with anti-cancer effects and few adverse side effects. This is the first report of SP in the literature.

リンク情報
DOI
https://doi.org/10.18632/oncotarget.25973
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/30214682
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132348
ID情報
  • DOI : 10.18632/oncotarget.25973
  • PubMed ID : 30214682
  • PubMed Central 記事ID : PMC6132348

エクスポート
BibTeX RIS